Navigation Links
DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma
Date:3/31/2008

Completion of Target Enrollment Expected in Fourth Quarter

BERKELEY HEIGHTS, N.J., March 31 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that the Data Safety Monitoring Board (DSMB) for AGENDA, a Phase 3 trial of Genasense (oblimersen sodium) Injection, which is the Company's lead oncology product, has recommended that the trial be continued as originally planned after initial review of blinded safety data from the study.

AGENDA is a Phase 3, randomized, double-blind, placebo-controlled trial that is intended to support global registration of Genasense for patients with advanced melanoma. The study is designed to confirm certain safety and efficacy results from Genta's prior randomized trial of Genasense combined with dacarbazine (DTIC) in patients identified by a biomarker who have not previously received chemotherapy. The co-primary endpoints of AGENDA are progression-free survival and overall survival.

At the end of the first quarter, the trial had accrued approximately 50 patients with approximately 60% of planned investigative sites having been initiated. Countries with sites currently open for enrollment include the U.S., Canada, Australia, France, Germany, Austria, and the Czech Republic. The trial is planned to open at approximately 90 sites worldwide, and most remaining sites are expected to initiate within the next 30 days. Target accrual of 300 patients is expected to complete in the fourth quarter of 2008, with initial data expected shortly thereafter.

"Investigator enthusiasm for AGENDA is quite high, and we are currently recruiting at our expected rate," said Dr. Loretta M. Itri, M.D., Genta's President, Pharmaceutical Development. "We believe the current rate, combin
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DSMB Again Supports Continuation of the Phase III Clinical Trial of Medidur(TM) FA for the Treatment of DME
2. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
3. ACR Supports American Cancer Society Inclusion of CT Colonography (Virtual Colonoscopy) as Recommended Screening Tool for Colorectal Cancer in New Screening Guidelines
4. New Clinical Data Further Supports Chromium Picolinates Role in Enhancing Brain Activity in Older Adults
5. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
6. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
7. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
8. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
9. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
10. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
11. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 Apnea Sciences ( www.apneasciences.com ) announced ... Aliso Viejo , California.  Jimmy Fallon ... growth and worldwide expansion, a new facility with expanded ... anti snore cure have exceeded our expectations and thus ... now in 23 countries and will be increasing to ...
(Date:12/22/2014)... -- ConvaTec, a privately-held medical products and technologies company, today ... Executive Officer of the company, effective December 22, 2014. ... "The Board of Directors of ConvaTec thanks Mr. Berger ... three years," said Magnus Lundberg , the Chairman ... the company is well positioned for the future."  The ...
(Date:12/22/2014)... , Dec. 22, 2014  Mark Farrah Associates ... providing a summary of the 2015 marketplace exchange ... trends.  According to a recent ... and Evaluation, Department of Health and Human Services) ... in individual medical plans through the Marketplace as ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Insights into the Marketplace and Individual Market Growth 2
... Radiation Therapy Services Holdings, Inc. (the “Company”), a ... for the first quarter ended March 31, 2011. ... million, an increase of 16.4% compared to $134.5 million in ... revenue was principally due to revenue from the May 2010 ...
... EDGE, N.J., May 11, 2011 Nephros, Inc. (OTC ... company developing and marketing filtration products for therapeutic applications, ... May 10, 2011 the Company received approval from the ... regulatory agency, to market its Dual Stage Ultrafilters (DSU) ...
Cached Medicine Technology:Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 2Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 3Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 4Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 5Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 6Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 7Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 8Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 9Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 10Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 11Nephros Receives Approval to Market Dual Stage Ultrafilters in Canada 2Nephros Receives Approval to Market Dual Stage Ultrafilters in Canada 3Nephros Receives Approval to Market Dual Stage Ultrafilters in Canada 4
(Date:12/22/2014)... Physicians in China are most eagerly awaiting ... non-Hodgkin’s lymphoma (NHL), according to a new report from ... firm. MabThera is the only biologic available to treat ... of NHL. , According to Kantar Health’s report, “Biosimilars ... NHL in China has been growing and is expected ...
(Date:12/22/2014)... Only weeks following the announcement that ... to have a battery manufacturer create 29 well-paying jobs ... ) is launching in Henderson to deliver yet ... strong manufacturing sector is going to build a stronger ... “and TalkLocal works with small businesses that rely on ...
(Date:12/22/2014)... Pasadena, CA (PRWEB) December 22, 2014 ... is now offering consultations for sleep apnea. Drowsy drivers ... crashes than drivers who are well-rested, and some experts ... on the roads as intoxicated drivers. Unfortunately, millions of ... to the American Academy of Sleep Medicine, about 18 ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once again joined ... logistics and support for one of Dallas’ largest holiday toy ... of giving back to the community in which it lives ... were Whataburger® and 99.5 The Wolf. , There is no ... to children who would otherwise not receive any is a ...
(Date:12/22/2014)... 21, 2014 A substantial percentage ... computed tomography (CT) to evaluate abnormal findings on ... cancer, according to a new study published online ... the findings show that radiologist recommendations for additional ... to patient care. , RAIs, which have grown ...
Breaking Medicine News(10 mins):Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:TalkLocal Launches in Henderson Weeks Following New Megafactory, New Jobs Announcement 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 3
... , GAITHERSBURG, Md., Sept. 21 ... Services (HHS) has placed an order for an additional 29 million ... H1N1 influenza virus. This brings HHS orders to date to ... value of approximately $453 million. Previous HHS orders for approximately ...
... patients more likely to finish radiation course, study finds ... interrupted radiation treatment is a common problem among Medicare ... has found. , Researchers analyzed data from 5,086 Medicare ... and 2003 and found that nearly 40 percent of ...
... around the country, care is delayed, complicated and ... the same language. The situation is particularly dire ... York. Now, USC computer scientists, communication specialists ... robust and effective speech-to-speech (S2S) translation system for ...
... 2009 Results of a multicenter study in ... low rate of complications in diabetic patients, will be ... scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF). ... on Clinical and Angiographic Outcomes in Diabetic Patients: Multicenter ...
... put your waistline at risk, according to a new study ... how other peoples, weight and food choices influence how much ... concern," write authors Brent McFerran, Darren W. Dahl (both University ... Morales (Arizona State University). "We decided to investigate how someone,s ...
... , NEW YORK, Sept. 21 PricewaterhouseCoopers, ... explore the business implications of one of the greatest domestic policy ... As the debate continues to rage in Washington, health industry ... upcoming PwC webcast series entitled 360 Degree Insight will ...
Cached Medicine News:Health News:MedImmune Receives U.S. Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza 2Health News:MedImmune Receives U.S. Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza 3Health News:Head, Neck Cancer Treatment Often Not Completed 2Health News:'The doctor can understand you now' 2Health News:'The doctor can understand you now' 3Health News:Researchers find drug-eluting stents safe, effective for PCI in diabetics 2Health News:Watching your weight? Beware of skinny friends with big appetites 2Health News:PricewaterhouseCoopers Announces Five-part Webcast Series on the Business Implications of Health Reform (Regardless of the Final Bill) 2Health News:PricewaterhouseCoopers Announces Five-part Webcast Series on the Business Implications of Health Reform (Regardless of the Final Bill) 3Health News:PricewaterhouseCoopers Announces Five-part Webcast Series on the Business Implications of Health Reform (Regardless of the Final Bill) 4
Cytomegalovirus IgM ELISA....
Small Incision Microforceps: Tano ILM Forceps...
Blunt tipped forceps with a thin tip angled at approximately 135 and hollowed out "notch" on the interior of the distal end. Tip is shaped like a pic when in the closed position. For membrane peeling...
Microforceps: Claes ILM Forceps...
Medicine Products: